LakeShore Biopharma Co., Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LSB Nasdaq 2836 www.ysbiopharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for LakeShore Biopharma Co., Ltd

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) - Apr 23rd, 2025 7:35 am
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - Dec 19th, 2024 7:05 am
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - Dec 12th, 2024 5:57 pm
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan - Nov 7th, 2024 6:00 am
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - Oct 29th, 2024 6:30 am
LakeShore Biopharma Advances with Rabies Vaccine Trial - Oct 26th, 2024 7:00 am
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine - Oct 25th, 2024 6:30 am
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - Oct 8th, 2024 6:30 am
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation - Sep 27th, 2024 5:00 am
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - Sep 10th, 2024 6:00 am
LakeShore Biopharma Announces Leadership Transitions - Sep 4th, 2024 6:00 am
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - Aug 15th, 2024 6:30 am
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - Jul 5th, 2024 5:00 am